Business Context and Reporting Period
This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) on September 14, 2018, covering events occurring on September 6, 2018. The company is a Delaware corporation focused on biopharmaceuticals.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. Specific financial items disclosed include:
- Dividend Declaration: A quarterly cash dividend of $0.15 per share on 6% Convertible Exchangeable Preferred Stock.
- Dividend Payment Date: November 1, 2018.
- Record Date: October 15, 2018.
- Director Compensation: Annual fee of $45,000 plus $4,000 for committee service for the newly appointed director.
- Equity Grant: Option to purchase 8,576 shares at an exercise price of $1.43 per share.
Material Changes
The primary material changes reported are corporate governance and capital structure events rather than operational financial shifts:
- Board Appointment: Robert J. Spiegel was appointed as a Class 3 Director effective September 6, 2018.
- Compensation Arrangement: Dr. Spiegel received stock options and a defined cash fee structure for his director services.
Guidance, Outlook, and Risks
Dividend Outlook: While the Board declared the current dividend, the filing explicitly states there is no assurance that future quarterly dividends will be declared. Future declarations will depend on financial analysis and surplus determinations.
Risks and Contingencies: The filing notes that there are no undisclosed transactions in which Dr. Spiegel has a material interest. No specific operational risks or contingencies were detailed in this report.
Investor Verification Checklist
- Verify the exact number of outstanding shares of 6% Convertible Exchangeable Preferred Stock to calculate total dividend liability.
- Confirm the vesting schedule and expiration date (September 6, 2028) of the 8,576 stock options granted to Dr. Spiegel.
- Review the company's most recent 10-Q or 10-K to assess the "surplus" status mentioned as a prerequisite for future dividends.
- Check for any subsequent filings regarding the payment of the November 1, 2018 dividend.